Rep. Sessions Introduces FAIR Act to Speed Up Access to Life-Saving Medicines From Overseas
This bill is currently in the early stages of the legislative process after being sent to the House Committee on Energy and Commerce. It is actively moving through the system, but no future hearings or votes have been scheduled yet. There is no companion bill listed for this legislation at this time.
Small biotech and pharmaceutical companies that have already won approval for their drugs in Europe, the UK, or Canada could use this new pathway to bring those treatments to the U.S. market much faster and at lower cost. The 30-day timeline and ability to leverage foreign regulatory dossiers reduces the paperwork burden that often disadvantages smaller firms compared to large pharma companies.
“include, with respect to each trusted international regulatory authority that authorized a covered product to be lawfully marketed in the foreign country involved, as described in subsection (b)(2)(A), an English translation (if necessary) of the dossier issued by such regulatory authority to authorize such marketing.”
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
No related news coverage found for this legislation yet.
Document Type
Congressional Bill
Official Title
FAIR ACT
Analysis generated by AI. Always verify with official sources.